


Welcome

to the

Healthcare Associated Infections Antimicrobial Resistance Webinar Series



Webinar Overview

- Schedule bi-monthly
- Intended audience hospital infection preventionists
- Upcoming topics:
 - The Three Rs August 2021
 - Candida auris October 2021
 - No webinar in December
 - MDROs February 2022





2022 schedule

- MDROs February 22, 2022
- Project Fristline April 26, 2022
- Project Firstline Environmental Cleaning June 28, 2022
- Project Firstline August 30, 2022
- Enterics October 25, 2022







MULTIDRUG RESISTANT ORGANISMS

Hannah Gallion

February 22, 2022

OUR MISSION:

To promote, protect, and improve the health and safety of all Hoosiers.

OUR VISION:

Every Hoosier reaches optimal health regardless of where they live, learn, work, or play.



Overview

- Definitions
- Antibiotic resistance
 - Spread
 - Mechanisms of action
 - Stewardship
- Antibiotic Resistant Organisms
 - AR threats
 - Carbapenem resistant organisms (CRO)
- Infection Control and Prevention



Definitions

- Multidrug-resistant organism (MDRO) an organism that is resistant to one or more agent in at least three classes of antibiotics, or that exhibits a classification of resistance that is of epidemiological concern (e.g. MRSA, VRE, ESBL, CRE)
- Carbapenem class of antibiotics (often thought of as the last line antibiotics)
- Carbapenemase enzyme produced by bacteria that breaks down most antibiotics, including carbapenem antibiotics



Antibiotic resistance

Intrinsic resistance


- The organism is naturally resistant to the antibiotic mechanism of action
 - Example: Porins in the cell wall are naturally too small to allow passage of the antibiotic.

Acquired resistance

- Vertical gene transfer
 - Example: Porin size
- Horizontal gene transfer
 - Example: Carbapenemase




Antibiotic resistance: How it happens






AR mechanisms





How antibiotic resistance spreads






Antibiotic stewardship

- Antibiotic stewardship is a set of commitments and activities designed to improve the treatment of infections and reducing the negative health impacts of antibiotic use.
- The CDC has issued "core elements" of antibiotic stewardship for:
 - Hospitals
 - Long-term care
 - Outpatient







Antibiotic-resistant organisms


AR threats

- Vancomycin-resistant Enterococcus (VRE)
- Vancomycin-resistant Staphylococcus aureus (VRSA)
- Clostridioides difficile
- Emerging resistance
- Carbapenem-resistant Enterobacterales (CRE)
- Carbapenemase-producing organisms (CPO)



VRE


- Enterococci are bacteria normally found in human intestines
- Most VRE infections are healthcare-associated
- VRE is spread from person to person
- VRE can also be transmitted through the environment via contaminated surfaces or equipment





VRSA


- Uncommon, but problematic
 - 15 infections reported in the US
- All identified have the *vanA* gene, which is commonly found
 in VRE
- Risk factors
 - Underlying health conditions
 - Catheter use
 - History of MRSA infections
 - Recent exposure to antibiotics





C. diff

- C. difficile infections (CDI) most often occur in older adults who have had recent exposure to antibiotics
- *C. difficile,* to date, has not been found to be resistant to any antibiotics of clinical relevance
- Patients diagnosed with a CDI should be placed on contact precautions





Emerging resistance

- Carbapenem-resistant Psuedomonas aeruginosa (CRPA)
- Carbapenem-resistant *Acinetobacter* baumannii (CRAB)



CRPA

- Pseudomonas is commonly found in the soil and water.
- Pseudomonas aeruginosa can cause infections in the blood, lungs, or other parts of the body after surgery.





CRPA

CRPA can spread person-to-person via

- Contaminated hands
- Contaminated equipment
- Contaminated surfaces

Risk factors:

- Ventilator-dependent
- Invasive devices such as catheters
- Wounds from burns or surgery



CRAB

- Acinetobacter is commonly found in soil and water.
- Acinetobacter baumanii can cause infections in the blood, urinary tract, lungs, and in wounds.
- Can colonize a patient without causing infections





CRAB

CRAB can be spread person-to-person via

- Hands of care-givers or family
- Contaminated surfaces
- Shared equipment

Risk factors:


- Recent healthcare exposure (particularly ICU stays)
- Ventilator-dependent
- Invasive devices such as catheters
- Open wounds



CRE

Definition: Any *Enterobacterales* that are not susceptible (i.e. intermediate or resistant) to a carbapenem antibiotic

- Enterobacterales can be resistant to carbapenems through several resistance mechanisms
- Carbapenemase production is currently the most concerning





CRE

Risk factors:

- Recent healthcare exposure
 - ACH, LTC, LTACH
- Recent medical procedures
- Recent invasive device use
 - Mechanical ventilator, PICC line, Foley catheter
- Recent antibiotic use
- Prior history of MDRO colonization or infection



Carbapenemase-producing CRE (CP-CRE)

Definition:


Enterobacterales that are not susceptible (i.e. intermediate or resistant) to at least one carbapenem antibiotics AND one of the following:

- Positive for carbapenemase production by a phenotypic test
- Not susceptible to at least three carbapenem antibiotics
- OR:
 - Positive for a carbapenemase gene marker (KPC, NDM, VIM, OXA, IMP)



2021 Indiana CP-CRE cases

2021 CP-CRE Cases by Mechanism





2021 Indiana CP-CRE cases by district

District 1: 76

District 2: 9

District 3: 14

District 4: <5

District 5: 43

District 6: 19

District 7: 7

District 8: <5


District 9: 6

District 10: <5





Carbapenemase-producing organisms





Facility level prevention strategies

- Hand hygiene
- Contact precautions 🗡
- Healthcare personnel education
- Smart use of invasive devices
- Laboratory notification
- Inter-facility communication \times

- Antibiotic stewardship
- Environmental cleaning
- patient and staff cohorting
- Screening contacts of CRE s
- Active surveillance testing *
- Chlorhexidine bathing





Hand hygiene

When caring for patients with MDROs, healthcare personnel should follow standard hand hygiene practices.

Wearing gloves is **NOT** a substitute for hand hygiene.

Alcohol-based hand sanitizer (ABHR) is effective against most MDROs, including *Candida auris* and is the preferred method for cleaning hands when they are not visibly soiled.

Soap and water should be used for *C. diff* and when hands are visibly soiled.



Contact precautions

When to use:

 All patients infected or colonized with a novel or targeted MDRO

*See Appendix A – Type and duration of Precautions Recommended for Selected Infections and Conditions of the CDC Guideline for Isolation Precautions

What to use:

- Gloves
- Gown
- Dedicated or disposable equipment (Clean and disinfect reusable equipment before use on another person.)



Inter-facility communication



Inter-Facility Infection Control Transfer Form • Updated December 2020

Page 2

Inter-Facility Infection Control Transfer Form

This form must be filled out for transfer to accepting facility with information communicated prior to or with transfer. Please attach copies of latest culture reports with if available.

Sending Healthcare Facility:

Infection Preventionist

Patient/Resident Last Name	First Name	Date of Birth	Medical Record Number
	•	•	•
Name/Address of Sending Facility		Sending Unit	Sending Facility Phone
Sending Facility Contacts	Contact Name	Phone	E-mail
Transferring RN/Unit			
Transferring physician			
Case Manager/Admin/SW			

Does the person* currently have an infection, colonization OR a	Colonization	Active
history Colonization Active infection of positive culture of a	or History	Infection on
multidrug-resistant organism (MDRO) or other or history potentially	(Check if Yes)	Treatment
transmissible infectious organism?		(Check if Yes)
Methicillin-resistant Staphylococcus aureus (MRSA)	□Yes	□Yes
Vancomycin-resistant Enterococcus (VRE)	□Yes	□Yes
Clostridioides difficile	□Yes	□Yes
Acinetobacter, multidrug-resistant	□Yes	□Yes
Enterobacteriaceae (e.g., f. coli, Klebsiella, Proteus) producing-Yes	□Yes	□Yes
Extended Spectrum Beta-Lactamase (ESBL)		
Carbapenem-resistant Enterobacteriaceae (CRE)	□Yes	□Yes
Pseudomonas aeruginosa, multidrug-resistant	□Yes	□Yes
Candida auris	□Yes	□Yes
COVID-19 Choose a Test Type: ☐ PCR ☐ POC Antigen	□Yes	□Yes
Other, specify (e.g., scabies, norovirus, influenza):	□Yes	□Yes





Eric J. Holcomb Governor Kristina M. Box, MD, FACOG State Health Commissioner

Inter-Facility
Infection Control
Transfer Form

This inter-facility infection control patient transfer form can assist in fostering communication during transitions of care for patients infected with MDROs, COVID-19, etc. The discharging facility should complete this transfer from and sign at the bottom after all fields are completed. Attach copies of pertinent records and latest laboratory reports to send with the patient to the receiving facility. This form has been adapted from the Centers for Disease Control and Prevention (CDC).

promote, protect, and improve the health and safety of all Hoosiers.

orth Meridian Street • Indianapolis, Indiana 46204 • 317-233-1325 • health in gov equal opportunity employer.



Inter-Facility Infection Control Transfer Form • Updated December 2020
Page 2

Does the person* currently have any of the following? (□Check here if none apply)							
☐ Cough or requires suctioning			☐ Hemodialysis catheter				
☐ Diarrhea			☐ Urinary catheter (Approx. date inserted				
□ Vomiting			☐ Suprapubic catheter				
☐ Incontinent of urine or stool			☐ Percutaneous gastrostomy tube				
☐ Open wounds or wounds requiring dressing change			☐ Tracheostomy				
☐ Central line/PICC Approx. date inserted:							
☐ Drainage (source):							
Is the person* currently in	n Transmission-B	laced Precautions	2 □ NO □ VES				
Type of Precautions (che	ck all that apply): 🔟 Contact 🔟 L	Proplet LI Airborne				
□Other: □Reason for Precautions:							
□ Reason for Pre	cautions.						
Vaccine	Date	Lot and Brand	Year administered	Does the person*			
	administered	(If known)	(If exact date	self-report			
	(If known)		not known)	receiving vaccine?			
Influenza				☐ Yes ☐ No			
(seasonal)							
Pneumococcal (PPSV23)				☐ Yes ☐ No			
Pneumococcal (PCV13)				☐ Yes ☐ No			
COVID-19				☐ Yes ☐ No			
Other:				☐ Yes ☐ No			
*Refers to patient or resident dep	ending on transferrin	g facility					
Required PPE							
				44			
				W			
Name of staff completing form (print):							
Signature:							
organism or							
If information communicated prior to tran <u>sfer:</u>							
Name of individual at re							
Phone of individual at receiving facility:							



Patient and staff cohorting


- Patients on contact precautions should be placed in a single room whenever possible.
- When single rooms are not available, people with the same MDROs may be housed together in the same room.
- If multiple patients with an MDRO are present, consider cohorting to one wing or unit.
- Consider cohorting healthcare personnel who provide the most regular care to these patients during a shift.



Screening for CP-CRE

Recommended for:


- Roommates of those with a positive CP-CRE test
- Units when a CP-CRE patient was not under contact precautions





Screening process

- Work with IDOH to determine who will be screened and when:
 - Testing laboratories have limited capacity and stick to a strict schedule
- IDOH will order kits from the AR Lab Network (ARLN) Wisconsin
- Kits can be shipped to either IDOH directly or to the facility where screening is to occur





Questions?

CONTACT:

Hannah Gallion

AR Epidemiologist

hgallion@isdh.in.gov

317-233-1306

